Biochemical and objective response to abiraterone acetate withdrawal: Incidence and clinical relevance of a new scenario for castration-resistant prostate cancer

Urology

Volumn 82, Issue 5, 2013, Pages 1090-1093

  Caffo, Orazio ^a   Palermo, Antonio ^a   Veccia, Antonello ^a   Maines, Francesca ^a   Chierichetti, Franca ^a   Berruti, Alfredo ^b   Galligioni, Enzo ^a  

^a SANTA CHIARA HOSPITAL   (Italy)

^b UNIVERSITY OF BRESCIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ABIRATERONE ACETATE; CABAZITAXEL; CHOLINE; DOCETAXEL; ENZALUTAMIDE; MITOXANTRONE; PREDNISONE; PROSTATE SPECIFIC ANTIGEN;

AGED; ANEMIA; ARTICLE; BONE SCINTISCANNING; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DRUG INDUCED DISEASE; DRUG RESPONSE; DRUG WITHDRAWAL; FATIGUE; FOLLOW UP; HEMATOLOGICAL PARAMETERS; HUMAN; HYPERTENSION; INCIDENCE; MALE; PRIORITY JOURNAL; REDUCTION; TREATMENT DURATION;

AGED; ANDROGEN ANTAGONISTS; ANDROSTADIENES; DISEASE PROGRESSION; FOLLOW-UP STUDIES; HUMANS; MALE; PREDNISONE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; TAXOIDS; TREATMENT OUTCOME;

EID: 84886949687     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2013.07.029     Document Type: Article

References (27)

1. M. Jarman, S.E. Barrie, and J.M. Llera The 16,17-double bond is needed for irreversible inhibition of human cytochrome p45017alpha by abiraterone (17-(3-pyridyl)androsta-5, 16-dien-3beta-ol) and related steroidal inhibitors J Med Chem 41 1998 5375 5381
2. G. Attard, A.H. Reid, and R. A'Hern Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer J Clin Oncol 27 2009 3742 3748
3. A.H. Reid, G. Attard, and D.C. Danila Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate J Clin Oncol 28 2010 1489 1495
4. D.C. Danila, M.J. Morris, and J.S. de Bono Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer J Clin Oncol 28 2010 1496 1501
5. J.S. de Bono, C.J. Logothetis, and A. Molina Abiraterone and increased survival in metastatic prostate cancer N Engl J Med 364 2011 1995 2005
6. K. Fizazi, H.I. Scher, and A. Molina Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study Lancet Oncol 13 2012 983 992
7. J.S. de Bono, S. Oudard, and M. Ozguroglu Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial Lancet 376 2010 1147 1154
8. H.I. Scher, K. Fizazi, and F. Saad Increased survival with enzalutamide in prostate cancer after chemotherapy N Engl J Med 367 2012 1187 1197
9. H. Gauthier, G. Bousquet, and D. Pouessel Abiraterone acetate withdrawal syndrome: does it exist? Case Rep Oncol 5 2012 385 387
10. L. Albiges, E. Auclin, and B. Rousseau Is there a withdrawal syndrome with abiraterone acetate (AA)? J Clin Oncol 31 2013 Abstract 89
11. R. Paul, and J. Breul Antiandrogen withdrawal syndrome associated with prostate cancer therapies: incidence and clinical significance Drug Saf 23 2000 381 390
12. H.I. Scher, S. Halabi, and I. Tannock Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group J Clin Oncol 26 2008 1148 1159
13. R.L. Wahl, H. Jacene, and Y. Kasamon From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors J Nucl Med 50 suppl 1 2009 122S 150S
14. M.E. Taplin, G.J. Bubley, and T.D. Shuster Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer N Engl J Med 332 1995 1393 1398
15. N. Mottet, J. Bellmunt, and M. Bolla EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer Eur Urol 59 2011 572 583
16. P.F. Schellhammer, P. Venner, and G.P. Haas Prostate specific antigen decreases after withdrawal of antiandrogen therapy with bicalutamide or flutamide in patients receiving combined androgen blockade J Urol 157 1997 1731 1735
17. E.A. Eisenhauer, P. Therasse, and J. Bogaerts New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer 45 2009 228 247
18. H. Miyamoto, M.M. Rahman, and C. Chang Molecular basis for the antiandrogen withdrawal syndrome J Cell Biochem 91 2004 3 12
19. C. Cai, S. Chen, and P. Ng Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors Cancer Res 71 2011 6503 6513
20. E.A. Mostaghel, B.T. Marck, and S.R. Plymate Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants Clin Cancer Res 17 2011 5913 5925
21. E. Efstathiou, M. Titus, and D. Tsavachidou Effects of abiraterone acetate on androgen signaling in castrate-resistant prostate cancer in bone J Clin Oncol 30 2012 637 643
22. K. Akakura, S. Akimoto, and T. Ohki Antiandrogen withdrawal syndrome in prostate cancer after treatment with steroidal antiandrogen chlormadinone acetate Urology 45 1995 700 704
23. N.K. Bissada, and A.T. Kaczmarek Complete remission of hormone refractory adenocarcinoma of the prostate in response to withdrawal of diethylstilbestrol J Urol 153 1995 1944 1945
24. N.A. Dawson, and D.G. McLeod Dramatic prostate specific antigen decrease in response to discontinuation of megestrol acetate in advanced prostate cancer: expansion of the antiandrogen withdrawal syndrome J Urol 153 1995 1946 1947
25. A. Sella, D. Flex, and A. Sulkes Antiandrogen withdrawal syndrome with cyproterone acetate Urology 52 1998 1091 1093
26. X.Y. Zhao, P.J. Malloy, and A.V. Krishnan Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor Nat Med 6 2000 703 706
27. C.J. Ryan, M.R. Smith, and J.S. de Bono Abiraterone in metastatic prostate cancer without previous chemotherapy N Engl J Med 368 2013 138 148